Intercell AG, the Austrian maker of vaccines for the prevention and treatment of disease, reported a 35.2% decline in revenue to €9.7 million for the second 2010 quarter, mainly due to the absence of milestone receipts from its collaborations.
Intercell AG, the Austrian maker of vaccines for the prevention and treatment of disease, reported a 35.2% decline in revenue to €9.7 million for the second 2010 quarter, mainly due to the absence of milestone receipts from its collaborations.